Lucky, I think the point was that DNDN has the potential to be a similar growth story as aapl not "take it out" as you summized. Fact is that once provenge gets approval and then subsequently gets approval for early stage prostate cancer and then followed by nuvenge, this company will be a tremendous money maker.
This is exactly my point. DNDN will throw off the kind of FCF that an apple is producing. Future numbers will be astounding. If Nuvenge gets approval next, their business model will rival the epogen/neupogen model amgen used.
No need for a buyout or partnership. Let them run with the big dogs!!!!
APPL's amazing numbers will buoy the techs tomorrow, and they needed it as the profit taking was fierce recently. This will help DNDN as a rising tide lifts all Nasdaq river boats. While we wait for DNDN to get out of the harbor that is....get the champagne bottles chilled, the USS Dendreon is about to embark.